Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Jazz Pharmaceuticals plc (JAZZ)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | $872.4M | $586.0M | $272.3M | $173.8M | $128.4M |
| Research & development | $782.7M | $884.0M | $849.7M | $590.5M | $505.7M | $335.4M | $299.7M | $226.6M | $198.4M | $162.3M | $135.3M | $85.2M | $41.6M | $20.5M | $14.1M | $25.6M | $36.6M |
| Operating expenses | — | — | — | — | — | — | — | $1.28B | $1.09B | $896.3M | $816.6M | $977.3M | $532.1M | $388.1M | $144.4M | $116.0M | $112.5M |
| Operating income | −$430.2M | $716.6M | $578.6M | −$65.5M | $170.3M | $378.1M | $532.4M | $614.8M | $528.8M | $591.7M | $508.2M | $195.6M | $340.3M | $197.8M | $127.8M | $57.8M | $15.9M |
| EBITDAderived | −$388.6M | $749.4M | $609.0M | −$35.2M | $197.0M | $396.8M | $547.7M | $630.0M | $541.9M | $603.5M | $518.1M | $329.3M | $422.4M | $272.1M | $135.7M | $66.5M | $25.0M |
| Net income | −$356.1M | $560.1M | $414.8M | −$224.1M | −$329.7M | $238.6M | $523.4M | $447.1M | $487.8M | $396.8M | $329.5M | $58.4M | $216.3M | $288.6M | $125.0M | $32.8M | −$6.8M |
| Basic EPSper diluted share | -$5.84 | $9.06 | $6.55 | -$3.58 | -$5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | $3.71 | $5.09 | $3.01 | $0.90 | -$0.23 |
| Diluted EPSper diluted share | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 | -$0.23 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 · 10b5-1 | Smith Mark DouglasDirector | SellOrdinary Shares | 1.2K | $230.55 | $266.7K | 9.7K |
| Jun 10, 2026Form 4 · 10b5-1 | Patil Neena MEVP & Chief Legal Officer | SellOrdinary Shares | 1.2K | $231.83 | $278.2K | 51.5K |
| Jun 1, 2026Form 4 · 10b5-1 | COZADD BRUCE CDirector | SellOrdinary Shares | 6.0K | $235.12 | $1.41M | 372.7K |
| May 28, 2026Form 4 | Pearce SamanthaEVP, Chief Commercial Officer | SellOrdinary Shares | 6.9K | $235.41 | $1.63M | 50.3K |
| May 28, 2026Form 4 · 10b5-1 | Patil Neena MEVP & Chief Legal Officer | SellOrdinary Shares | 1.2K | $236.97 | $282.5K | 52.6K |